Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Chris Kim
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Beta
- 0.74
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -27.13
Financials
Net Income
$-1.41MEBITDA
$-1.38MFree Cash Flow
$-970.0KEPS (diluted)
$-0.03Shares Outstanding (diluted)
48.40M+495.5%Operating Expenses
$1.38MCash & Debt
$3.02MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-10.21M | $-0.43 |
| 2024 | $0.00 | $-2.90M | $-0.40 |
| 2023 | $0.00 | $-1.23M | $-0.15 |
| 2022 | $0.00 | $-2.93M | $-0.08 |
| 2021 | $0.00 | $4.37M | $0.13 |
Valuation
LIMNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·21h ago·Neutral
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-50 (the “Reverse Stock Split”), which was approved by stockholders at the Company's 2026 Annual Meeting of Stockholder…
View source ↗
Insider trading
Open-market buys and sells by LIMN officers and directors.
No open-market trades in the recent filings. All 16 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.